12,372 trials
Influenza
Primary: Humoral Immune Response in Terms of Hemagglutination Inhibition (HI) Antibodies Against Each of the 4 Vaccine Influenza Strains. — 130.4; 57.3; 404.8; 355.5 Titers
Anemia
Primary: Number of Subjects Achieving 'Clinical Success'. Clinical Success is Defined as an Increase in Hemoglobin of ≥ 2.0 g/dL — 187; 139 participants
Blood Coagulation Disorders · Hemophilia A
Primary: Part A - Area Under the Drug Concentration-time Curve (AUC) — 1889.23; 1583.91 Int.units x hours/deciliters (IU*h/dL)
Healthy
Primary: Prostate-specific Antigen (PSA) — 0.8; 0.9; 0.7; 0.4 ng/mL
Early Rheumatoid Arthritis
Primary: Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26 — 42.9; 44.0; 56.6; 60.2 percentage of…
de Novo Kidney Transplant Recipients · Renal Transplantation
Primary: Treatment Failure Rate — 3; 10; 2 Participants
Atrial Fibrillation
Primary: Event Rate of Stroke/Systemic Embolism During the Intended-treatment Period — 1.62; 3.63 Percentage of events — p=<0.00001
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV)…
Idiopathic Short Stature
Primary: Absolute On-target Difference (AOTD) at 24 Months — 0.603; 0.625 Standard Deviation Score (SDS) — p=0.5762
Amblyopia
Primary: Distribution of 10-week Amblyopic Eye Visual Acuity — 1; 0; 0; 0 participants
Cytomegalovirus Infection
Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants
Upper Respiratory Infections
Primary: Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup — 34.6 mm
Epilepsy
Primary: Number of Participants With a >=50% Reduction in Partial-onset Seizure (POS) Frequency From Baseline — 22; 16; 22; 29 participants
Chronic Obstructive Pulmonary Disease
Primary: Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First). — 155.0; 171.7 Days
Social Anxiety Disorder
Primary: The Liebowitz Social Anxiety Scale (LSAS) — 41.0; 33.3 units on a scale — p=.015